Postoperative Adjuvant Therapy for Stage II-III Gastric Cancer
Trial Parameters
Brief Summary
For patients with stage II-III gastric cancer after radical D2 resection and R0 resection, postoperative adjuvant therapy guided by ctDNA-MRD (MRD-GATE external cohort) was not inferior to the standard chemotherapy regimen (this cohort).
Eligibility Criteria
Inclusion Criteria: 1. Patients who have undergone D2 gastrectomy, achieved R0 resection, and are pathologically diagnosed with stage II-III gastric cancer. 2. No preoperative neoadjuvant or adjuvant therapy received. 3. Voluntary participation with signed informed consent, demonstrating good compliance and willingness to cooperate with follow-up procedures. 4. Age between 18-75 years, with no gender restrictions. 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. 6. Estimated survival of 6 months or more. 7. Baseline hematological and biochemical parameters within specified limits: a. Hemoglobin ≥ 80g/L. b. Absolute neutrophil count ≥ 1.5×10\^9/L. c. Platelet count ≥ 100×10\^9/L. d. Aspartate or alanine aminotransferase ≤ 2.5 times the upper limit of normal. e. Alkaline phosphatase ≤ 2.5 times the upper limit of normal. f. Thyroid-stimulating hormone (TSH) ≤ 1 times the upper limit of normal (if abnormal, T3 and T4 levels must be normal). Exclusion Criteria: 1. Pr